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Abstract
Background: Next Generation Sequencing (NGS) is expected to lift molecular diagnostics in clinical oncology to
the next level. It enables simultaneous identification of mutations in a patient tumor, after which targeted therapy
may be assigned. This approach could improve patient survival and/or assist in controlling healthcare costs by
offering expensive treatment to only those likely to benefit. However, NGS has yet to make its way into the clinic.
Health Technology Assessment can support the adoption and implementation of a novel technology, but at this
early stage many of the required variables are still unknown.
Methods: Scenario drafting and expert elicitation via a questionnaire were used to identify factors that may act as
a barrier or facilitate adoption of NGS-based molecular diagnostics. Attention was paid to predominantly elicit
quantitative answers, allowing their use in future modelling of cost-effectiveness.
Results: Adequately informing patients and physicians, the latters’ opinion on clinical utility and underlying
evidence as well as presenting sequencing results within a relevant timeframe may act as pivotal facilitators.
Reimbursement for NGS-based testing and accompanying therapies (both general and in case of off-label
prescription) was found to be a potential barrier. Competition on the market and demonstrating clinical utility may
also be challenging. Importantly, numerous quantitative values for variables related to each of these potential
barriers/facilitators, such as such as desired panel characteristics, willingness to pay or the expected number of
targets identified per person, were also elicited.
Conclusions: We have identified several factors that may either pose a barrier or facilitate the adoption of NGS in
the clinic. We believe acting upon these findings, for instance by organizing educational events, advocating new
ways of evidence generation and steering towards the most cost-effective solution, will accelerate the route from
bench-to-bedside. Moreover, due to the methodology of expert elicitation, this study provides parameters that can
be incorporated in future cost-effectiveness modeling to steer the development of NGS gene panels towards the
most optimal direction.
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Background
In recent years, the cost and time required for large
scale sequencing have rapidly decreased, catalyzing an
increased understanding of genetic variation in both
health and disease. Relatively cheap next generation se-
quencing (NGS) may confer great benefit in a clinical
setting as well, especially in oncology [1]. Many insti-
tutes are currently developing NGS-based gene panels,
which investigate the presence of multiple mutations in
a single tumor at once. Subsequently, a specific targeted
therapy may be assigned thereby potentially improving
clinical outcome [2]. While many experts advocate that
simultaneous testing of genes also has the potential to be
more cost-effective than performing sequential single-
gene assays, this has yet to be shown [3]. We define a
NGS gene panel as “a multiplex predictive test which ex-
plores limited regions of tumor DNA/RNA for aberrations
that can be used as a molecular target for therapy”.
Meanwhile, NGS has reached the molecular diagnostic
market and is expected to slowly replace single-gene
molecular diagnostic tests [4]. Currently, within the
Netherlands, hospitals have started with the implemen-
tation of NGS for diagnostics, using techniques ranging
from single gene testing to small, medium or large NGS
panels. Beyond biology, the adoption of NGS for large
scale molecular diagnostics will also depend on a variety
of organizational, societal and economic factors [5, 6].
For instance, will hospitals be able to supply tissue meet-
ing NGS requirements? Are physicians up to date on
pharmacogenomics to use such a test in the clinic? And
importantly, can society afford personalized medicine at
all, given the costs associated with sequencing as well as
extremely expensive targeted [5, 6]? Due to the increased
pressure to control ever-rising healthcare costs, reliable
input regarding novel technologies on these factors is
becoming increasingly more important. To our know-
ledge there are as yet no widely accepted national pol-
icies on NGS-based panels apart from the French
initiative to centralize services for a specified number of
molecular tests in regional centers under the Institut
National du Cancer (INCa) umbrella.
A commonly used methodology to estimate and evalu-
ate the impact of a novel technology is Health Technol-
ogy Assessment (HTA), which is increasingly being used
to support policy and reimbursement decisions regard-
ing medical interventions [7]. Early stage TA can help to
expedite further development and guide the adoption of
a promising technology in the clinic [8]. We have previ-
ously performed such an early TA assessment for the
introduction and adoption of a 70-gene prognosis-
signature for breast cancer [9, 10]. As part of this assess-
ment, to fill in evidence gaps in cost-effectiveness
analysis, we used scenario drafting as originally devel-
oped by Royal Dutch Shell. By describing potential
directions of development, Shell is able to anticipate
events possibly affecting their market position and
timely adapt corporate strategy [11–13]. In case of the
70-gene array, we drafted several scenarios that repre-
sented likely patterns of its diffusion across the health
care system focusing on features that were still likely to
change during development, such as clinical, economic,
patient-related, and organizational parameters [10].
Some of these were subsequently incorporated into a
cost-effectiveness analysis [14].
In this paper, we report on scenario drafting concern-
ing the adoption and implementation of NGS gene
panels in clinical oncology among professionals. Our ob-
jective was first; to identify critical barriers and facilitators
that may affect the speed of adoption of such panels in
clinical practice and second; to estimate values of quanti-
tative parameters for future cost-effectiveness modeling.
Methods
Background research
We first interviewed in-house experts (Netherlands Can-
cer Institute) specialized in (molecular) diagnostics, pa-
tient management and/or next-generation sequencing to
identify variables that are likely to affect the speed of
adoption of NGS-panels (Fig. 1). More info was gathered
using Pubmed and Google Scholar, by searching for recent
papers using (combinations of) the terms “cancer”/”oncol-
ogy”/”tumor”/”clinical” + “personalized medicine”, “preci-
sion medicine”, “genomic medicine”, “stratified medicine”,
“targeted therapy”, “tailored therapy”, “pharmacogenom-
ics”, “next-generation sequencing”, “capture-based sequen-
cing”, “multiplex sequencing”, “molecular diagnostics”,
“companion diagnostics”, “genetic testing”, “predictive bio-
markers”, “economics”, “cost-effectiveness”, “perspectives”,
“costs”, “implementation”, “challenges”, “reimbursement”,
“storage”, “data”, “patients”, “physicians”. This resulted in
thousands of papers often discussing the same topics.
We selected papers for our background research that
discussed multiple issues surrounding adoption and im-
plementation of NGS simultaneously, highlighted the
perspective of several stakeholders, were written in
English and published no longer than 10 years ago,
resulting in a set of 106 papers.
Scenario drafting
Using all the gathered background information, we
drafted one baseline scenario describing the diffusion of
NGS gene panels for personalized cancer treatment in
general and twelve “what if” scenario deviations, which
represent developments that may positively or negatively
affect the speed of diffusion. Next, we drafted a ques-
tionnaire to elicit expert opinion on the specifics and
likelihood of our “what-if” scenarios.
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Questionnaire construction & distribution
First, forty-one questions were specifically designed to
elicit quantitative answers in order to use our data in fu-
ture cost-effectiveness modeling. Since we are planning to
perform such modeling for at least colorectal cancer
(CRC), non-small cell lung cancer (NSCLC) and melan-
oma, we often posed questions for each patient population
separately. Input from Netherlands Cancer Institute (NKI)
employees was used to prevent ambiguity in language.
Next, subsets of questions were used to construct
three questionnaires (Additional file 1), each one specif-
ically tailored to the expertise of physicians, biologists or
policy workers. All versions were accompanied by the
same cover letter providing background on NGS gene
panels and explaining the purpose of our research. At
the end, respondents were asked to rate the likelihood of
the twelve scenarios on a scale from 0-100 %.
The questionnaires were distributed via email to a
sample of NKI employees and external (partly inter-
national) stakeholders. Given the complexity of NGS-
based diagnostics and in view of the very early stage of
development and uncertainty surrounding clinical utility,
we decided to focus on technical experts and clinicians
first. External recipients had been in previous contact
with the hospital or were selected because of published
work on related matters. After a week, a reminder was
sent to non-responders.
Data collection and analysis
A database of respondents answers was created using
Adobe Acrobat X Pro and variation among expert opin-
ions was assessed visually using colored 2D-dotplots as
well as by descriptive statistics using IBM SPSS statistics.
If answers were illegible these were excluded from our
analysis and we also assessed whether (missing) values
could be attributed to a certain respondent subgroup
(e.g. profession, specialization, internal/external).
Consent statement
This study was made possible by elicitation of expert’
opinion via a questionnaire. The procedure was verified
with the protocol review committee. Participation was
on voluntary basis and filled-in questionnaires were
anonymized prior to analysis. Upon invitation, experts
were informed that their answers would be used an-
onymously to improve scenarios. No patients nor chil-
dren, parents or guardians were involved.
Ethics statement
According to institutional guidelines, it was verified with
the protocol review committee that no ethical review
nor consent was needed for this study.
Results
Questions posed in our survey often relate to several
scenarios simultaneously, therefore we have clustered re-
sults into the following domains: social factors; technical
factors; market access; clinical utility & evidence gener-
ation and reimbursement. For every domain we first re-
port the estimated likelihood of scenario occurrence in
percentages (Table 2) and next we discuss our findings
on associated parameters (Table 3) and their relevance
for cost effectiveness modeling. Summarizing these
Fig. 1 Overview of methodology. CEA = Cost-effectiveness analysis
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findings, we have labeled a scenario as a potential facili-
tator or barrier. All scores are represented as mean re-
sults ± standard deviation. In some cases absolute
numbers are mentioned to depict clear disagreement
among respondents.
Respondent characteristics
In total, 29 questionnaires were completed by 14 physi-
cians (specialized in general oncology, pulmonology,
dermatology or pathology), 11 biologists (research and
diagnostics), three policy workers and one epidemiolo-
gist; 12 from within and 17 from outside the NKI
(Table 1).
Social factors
The likelihood of scenario 1 occurrence within 5 years,
in which patients will be interested in NGS panels and
will demand lots of information on this molecular ap-
proach was estimated at 66,5 % (±28,1) (Table 2).
When presented questions related to this “what-if”
scenario, clinicians among respondents estimated that
this will entail 65,3 % (±32,1) of patients suffering from
metastatic cancer, compared to 28,3 % (±29,2) of pa-
tients with non-metastasized disease (Table 3). Respon-
dents whom themselves are skeptical about using NGS
for adjuvant treatment, estimated larger differences be-
tween the former two patient groups (Additional file 2).
Additionally, they felt that 78,2 % (±16,1) and 41,5 %
(±26,6) of those patients respectively would be willing to
enroll in a clinical trial on a new targeted therapy. The
number of extra minutes during a patient’s first consult
to adequately inform them about NGS-based genetic
testing was thought to lie around 13,2 (±12,4) minutes.
Physicians themselves likely require extra education on
NGS as well, estimated at 25,1 (±26,1) hours.
Scenario 2, also related to social acceptability, described
a situation in which physicians will remain unconvinced
of the clinical benefit of large scale sequencing. The ma-
jority of respondents (10 out of 15) believed this scenario
has a 16,5 % (±8,8) chance of occurring, while some (5/15)
believed 64,0 % (±8,9) to be a more realistic number
(Table 2).
Detailed questions on scenario 2 revealed that respon-
dents estimate 84,9 % (±23,6) of physicians to adopt
NGS gene panels if such panels have at least been vali-
dated by a phase 3 randomized controlled trial (Table 3).
However, estimates of adoption decline in case of lower
level studies (e.g. 62,3 % ±20,3 for a prospective observa-
tional study; 39,6 % ±22,6 for a retrospective observa-
tional study; 16,7 % ±8,6 for lower levels of evidence).
39 % of respondents themselves believe that NGS gene
panels should only be offered to patients with advanced
disease, but an equal percentage believe NGS should
already be offered as an adjuvant solution. Others (22 %)
found level of evidence,–toxicity and-benefit the most
important indicators for use, irrespective of stage.
Technical factors
Respondents rated the likelihood of scenario 3, describ-
ing a maximum of ten days turn-over time from biopsy
to results, at 84,4 % (±18,5). When asked for their own
preferences, a maximum of 17,8 (±21.3) days was indi-
cated (Table 2).
NGS gene panels can vary in all kind of characteristics,
including what type of tissue preservation (formalin-
fixed paraffin embedded-FFPE-or fresh frozen-FF-
biopsies) they can handle. When presented with scenario
4, in which only FF tissue would be able to generate reli-
able sequencing results, some respondents (11 out of 24)
estimated a 86,8 % (±13,1) chance that this requirement
will limit NGS adoption by medical professionals. Others
(13 out of 24) found scenario 4 less likely to occur and
estimated its likeliness to occur at 16,2 % (±9,4). This
distinction was also found among physicians alone: 8
out of 11 estimated a 83,8 % (±19,2) chance of scenario
occurrence, while the remaining opted for a 14,0 %
(±8,9) chance.
An important parameter for scenario 4, the percent-
age of Dutch institutes capable of supplying FF biop-
sies, was estimated at 50,5 % (±36,5) (Table 3). Other
questions into technical parameters that may affect
both scenarios 3 and 4 revealed preferences for a min-
imal sensitivity/specificity of 90,5 % (±5,7) and 89,0 %
(±9,7) respectively and a maximally acceptable failure
rate (e.g. in case of too little DNA available) of 18,4 %
(±20,1). If re-biopsy would be required to obtain reli-
able results, respondents expect a percentage of pa-
tients to decline (eg. 33,3 % ±23,6 in CRC; 30,0 % ±22,9
in NSCLC; 8,5 % ±5,9 in melanoma). Re-biopsy may
even be unfeasible in a certain number of cases (19,2 %
±11,1 in CRC; 22,9 % ±16,0 in NSCLC; 9,3 % ±10,0 in
Table 1 Respondent characteristics
Profession Respondents (n)
NKI External
Physicians Oncologist 5 4
Othera 4 1
Biologist Research 2 5
Diagnostics 0 4
Policy 0 3
Epidemiologist 1 0
Total 12 17
Respondent specifics are described here, distinguishing between Netherlands
Cancer Institute employees (NKI) and external respondents. 4 respondents
were situated outside the Netherlands.a Other: specializations beyond medical
oncology included pathology (2), pulmonology (1), dermatology (1) or
surgery (1)
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melanoma). Respondents believed that residual tissue
should be stored for minimally 24,2 (±22,1) years. For
future reference, sequencing results carrying informa-
tion beyond the scope of current treatment should be
kept for at least 22,6 years (±21,4).
Reimbursement
Scenario 5 depicts a situation where opposing insti-
tutes draw up a “minimal requirements” agreement
on NGS gene panels and consequently a national re-
imbursement policy is implemented. Likelihood of
scenario occurrence was estimated at 40,3 % (±24,1)
(Table 2).
Addressing a related parameter, respondents felt that
NGS-panel-compared to single gene diagnostics would
justify €380,8 (±316,6) additionally (Table 3). The prob-
ability to opt for an FFPE-based NGS panel if priced at
€1000 averaged at 44 % (±44,0).
Table 2 Baseline-and what-if scenarios
Baseline scenario: “Within 5–10 years, NGS gene panels will become common practice for personalized treatment in oncology”
Domain What-if scenarios (likelihood ± SD) Effect Barrier/facilitator
Social 1. Patient perspective (66,5 ± 28,1; n = 13)Patients will
demand lots of information on NGS-based panels, but
will nevertheless be very interested in using them.
Higher uptake and more compliance Pivotal facilitators
2. Medical professional perspective (16,5 ± 8,8; n = 10 and
64,0 ± 8,9; n = 5)Medical professionals remain
unconvinced of the clinical benefit that can be gained
using NGS-panels and targeted therapy.
Technical 3. Organization (84,4 ± 18,5; n = 25)The time required for
preparation, NGS and analysis of a biopsy will decrease
so that patients will receive results within ten days after
biopsy.
Higher uptake and less failures
4. FF versus FFPE (86,8 ± 13,1; n = 11 and 16,2 ± 9,4;
n = 13)If reliable sequencing results can only be
obtained by using FF tissue, the use of NGS-based
panels will remain limited.
Reimbursement 5. Reimbursement (40,3 ± 24,1; n = 18)A ‘minimal
requirements’ agreement between institutes
developing NGS-based gene panels has resulted in
national reimbursement policy of such panels.
Less uptake Pivotal barriers
Clinical utility and evidence
generation
6. Clinical Utility (50,4 ± 31,4; n = 25)Demonstrating
clinical utility of NGS-panels will take at least a couple
more years, adoption of this technology will only
succeed once that point is reached.
No improved survival and slow release
of new target/therapy combinations
7. Actionable targets (55,2 ± 23,7; n = 26)The number of
mutations identified by NGS panels that can actually be
targeted by therapy, remains limited.
8. Off-label prescription (49,2 ± 31,1; n = 18)The medical
community becomes more lenient towards off-label
treatment.
9. Revised evidence generation (65,5 ± 27,9; n =
29)Evidence from less time-consuming clinical studies
than RCT III, will be considered valid to include new
targets in NGS-based gene panels
Market access 10. Competition from a different field (45,0 ± 21,7;
n = 25)Another type of technology enters the Dutch
healthcare, decreasing the popularity of NGS-based
gene panels.
Less uptake
11. Competition within the field (64,2 ± 21,9; n =
12)Another NGS-based panel outcompetes the
NKI-panel, regardless of its additional features.
12. Intellectual property (45,6 ± 28,7; n = 25)Competitors
offering NGS-based panels will be reluctant to share
new biological insights generated by NGS-panels with
each other, thereby decelerating the improvement of
clinical utility for patients.
Twelve potential deviations from a baseline scenario in which NGS-based gene panels are implemented in clinical oncology. Respondents were asked to rate the
likelihood of their occurrence on a scale from 0-100 %. Since several scenarios were presented to relevant professions only, combined with some missing values,
the number of respondents per scenario varied
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Clinical utility & evidence generation
Scenario 6, in which the route to demonstrating clinical
utility still requires several years, was assessed 50,4 %
(±31,4) likely. Scenario 7 described a theoretical limiting
factor to that route, in which the number of therapeutic
targets identified by NGS panels would remain limited.
The chance of this scenario occurring was estimated at
55,2 % ±23,7 (Table 2).
Related to these scenarios, several parameters esti-
mates were elicited (Table 3). Presented with the charac-
teristics of the NKI-panel, respondents would expect to
find 6.6 (±7,5) potential targets per patient. Also, they
believe that in the following 5 years, 22,5 (±20,4) novel
and approved targeted therapies (for new targets) will
hit the market. Furthermore, they estimated that in
30,2 % (±26,5) of cases using NGS, a target for which
off-label treatment is available will be identified.
Scenario 8, in which the medical community would
become more lenient towards prescribing off-label medi-
cation, was found 49,2 % (±31,1) likely to occur
(Table 2).
Under circumstances as described above, respondents
expect 44,6 % (±31,6) of physicians to be willing to pre-
scribe off-label therapy (regardless of reimbursement)
(Table 3). The propensity of respondents themselves to
do so varied given the level of evidence supporting a
Table 3 Parameters and corresponding questions
Domain Parameter Q Average ± SD
Social factors Patients interested in NGS (prim/meta) Q1 28,3 ± 29,2/65,3 ± 32,1
Patients interested in trial (prim/meta) Q2 41,5 ± 26,6/78,2 ± 16,1
Consult extra (min) Q3 13,2 ± 12,4
Education extra (hrs.) Q10 25,1 ± 26,1
NGS Adoption given: RCT3 Q6 84,9 ± 23,6
Pros. observational 62,3 ± 20,3
Retro. observational 39,6 ± 22,6
Lower levels 16,7 ± 8,6
Technical Factors Max. turnover rate (days) Q9 17,8 ± 21,3
Dutch institutes able to supply FF Q16 50,5 ± 36,5
Min. sensitivity/specificity Q15 90,5 ± 5,7/89,0 ± 9,7
Max. failure rate Q17 18,4 ± 20,1
Re-biopsy decline: CRC Q18 33,3 ± 23,6
NSCLC 30,0 ± 22,9
Melanoma 8,5 ± 5,9
Re-biopsy unfeasible: CRC Q19 19,2 ± 11,1
NSCLC 22,9 ± 16,0
Melanoma 9,3 ± 10,0
Min. storage tissue (yrs.) Q14 24,2 ± 22,1
Min. storage NGS results (yrs.) Q13 22,6 ± 21,4
Reimbursement Pay extra for NGS panel (euro) Q12 380,8 ± 316,6
Probability opt for NGS panel if €1000 Q40 44,0 ± 44,0
Clinical utility and evidence generation Nb. Targets per patient Q37 6,6 ± 7,5
Nb. new therapies in five years Q29 22,5 ± 20,4
Off-label therapy required Q22 30,2 ± 26,5
Physicians willing to prescribe off-label Q23 44,6 ± 31,6
Probability reimbursement off-label Q27 28,0 ± 32,0
Lenient towards off-label (yrs.) Q26 9,8 ± 12,4
Market access Min. years NGS common practice Q33 6,5 ± 6,3
Min. years competition other technology Q35 9,6 ± 5,5
Depicted are the mean results (percentages unless stated otherwise) and standard deviations on quantitative parameters, in order of appearance. Column Q refers
to the number of the corresponding questions in the questionnaire (Additional file 1). NGS next generation sequencing, Prim primary cancer, Meta metastatic
cancer, FF fresh frozen [tissue preservation]
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target/therapy combination and stage of disease (Table 4).
They felt that the chance of reimbursement for off-label
treatment is low (28,0 % ±0,32) and that the medical
community will minimally need 9,8 (±12,4) years to be-
come more lenient towards it.
Some respondents pointed out that targeted therapies
require novel/alternative study designs for evidence gener-
ation. Respondents estimated that there is a 65,5 %(±27)
chance that revised evidence generation will be generally
accepted, as described in scenario 9 (Table 2).
Roughly half of respondents themselves consider evi-
dence from prospective-(46 %) or retrospective observa-
tional studies (50 %) valid to base medical decisions on.
14 % chose the option “Lower levels of evidence” and
18 % ticked “Other” which some supplemented with
suggestions such as basket-and adaptive protocols as ac-
ceptable designs. 72 % of respondents rated the alterna-
tive endpoint progression-free-survival valid to base
medical decisions upon, compared to 52 % in case of
time-to-progression,−41 % in case of disease-free-
survival (41 %) and–41 % in case of response rate.
Market access
Respondents estimated a 45,0 % (±21,7) chance that an
alternative technology to NGS will enter the market and
decrease NGS popularity, as described in scenario 10.
Scenario 11, in which NGS competitors’ propensity to
share generated biological insight was described as reluc-
tant, was deemed 45,6 % (±28,7) to occur (Table 2).
Addressing parameters specific to these scenarios, re-
spondents estimated that it will minimally take 6,5
(±6,3) years before NGS gene panels become widely im-
plemented in the clinic and that another technology is
likely to take over the market within 9,6 (±5,5) years
(Table 3). According to some (60 %), acquired resistance
to therapy may be a limiting factor of adoption of NGS.
A competing technology will probably still be based on
sequencing, but complemented by proteomics/immuno-
therapy or diagnostics on circulating tumor cells. Novel
drug sensitivity assays were also mentioned.
Discussion
Using scenario drafting on the basis of expert elicitation,
we have been able to identify a number of critical factors
that may affect the speed of adoption of NGS gene
panels in clinical oncology as well as variables that may
be incorporated in future cost-effectiveness modeling.
The outlook of patients and physicians towards this
novel technology appears to be one of the pivotal facili-
tators of adoption of NGS panels in the clinic. Although
not asked to patients themselves, our results indicated
that physicians estimation was that patients’ perspective
on NGS panels is likely to be highly positive (~66,5 %),
coinciding with studies on pharmacogenomics/-genetics
that did include patients in their study population [15,
16]. Popularity amongst patients will probably be posi-
tively related to stage of disease, although this distinction
seemed related to respondents’ personal opinions. Thus,
further investigations into patients’ perspective may be
advisable, both in general as well as to confirm the valid-
ity of respondents’ estimations. Nonetheless, our results
do imply that social factors among patients are likely fa-
vorable towards the implementation of NGS panels in
the clinic.
We also found that most physicians (~85 %) are prob-
ably willing to use NGS panels in clinical practice, given
Table 4 Respondent propensity to prescribe off-label therapy
Level of evidence Adjuvant (n = 16) Metastatic (n = 26)
At least validated by an RCT3 in another type
of cancer and an observational study for the
type cancer you intent to treat
6/16; 37,5 % 7/26; 27,0 %
At least validated by a RCT3 for another type
of cancer
2/16; 12,5 % 3/26; 11,5 %
At least validated by an observational study in
another type of cancer
4/16; 25 % 6/26; 23,1 %
Other, namely never 2/16; 12,5 % 1/26; 0,04 %
Other, namely descriptive: “tissue-based labelling should be
changed” (1/16; 6,25 %), “Bayesian
approach should be used” (1/16; 6,25 %)
“only as part of a trial” (2/26; 0,08 %) and 7 individual
comments (0,04 % each) including “Based on RCTII data”,
“Based on RCTII with molecularly selected patients”,
“Casuistic evidence from other disease entities”, “Any
time”, “tissue-based labelling should be changed”,
“Bayesian approach should be used”, “Depending on
costs”
Respondents were presented with the following hypothetical situation: “A NGS gene panel was only able to identify one molecular target in a patient’s tumour.
However, the corresponding targeted therapy has not been registered for that type of cancer yet, thus off-label treatment may be the only option” They were
then asked based on what level of evidence and stage of disease they would prescribe the therapy. The question regarding the metastatic setting was asked in
all versions of the questionnaire, while the question for the adjuvant setting was only posed in the physicians and policy version. Therefore, the number of
respondents per column differs
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validated evidence from RCTs. Lower levels of evidence
are likely to have a large negative impact on adoption
rates. Naturally, such stringent levels of evidence come
at a cost. However, opting for a prospective observa-
tional study compared to a RCT might save time, money
and effort, while still convincing the majority (~60 %) of
physicians. Importantly, the average physician will re-
quire ~25 h of extra training on pharmacogenomics be-
fore being able to use NGS panels clinically. Thus,
organizing educational activities will definitely be re-
quired prior to NGS implementation. Fortuitously, ad-
vancing physicians’ knowledge on pharmacogenomics is
likely to increase adoption rates even further, as previ-
ously stated by Stanek et al. (2012) [17]. Thus, while
most physicians stand positive towards NGS, investing
in the level of supporting evidence as well as education
on NGS panels may even increase the speed of its
diffusion.
Next to estimating that the adoption of NGS will
benefit from current social perspectives, experts also
found it highly feasible that analysis of biopsies can be
performed within a clinically relevant timeframe of
10 days. Thus, achievability of timely logistics may also
be labeled as a so-called facilitator of diffusion.
However, obtaining a biopsy in itself and whether ac-
quired tissue will meet the criteria for NGS-based ana-
lysis may be troublesome on some occasions. While
previous investigations have concluded that most Euro-
pean institutes are able to supply FF biopsies meeting
standards for RNA/DNA analysis [9, 18], our respon-
dents’ opinions regarding this matter varied extensively.
Thus, obtaining and preserving such biopsies may still
require a learning curve for a large number of hospitals
and could potentially pose a barrier for widespread
adoption of NGS panels. The 90,5 % sensitivity,
89,0 % specificity or 18,4 % maximum failure rate de-
scribed in this article may serve as a useful guideline
during development regarding decisions on the trade-
off between user-friendliness and publically desired
technical specifications and as such, may help in in-
creasing adoption rates.
One of the general barriers for NGS implementa-
tion and adoption includes low probability of reim-
bursement. This could pose a major barrier for
implementation, since costs associated with NGS test-
ing − while dropping-and targeted therapies themselves
are still not affordable for patients themselves. Ac-
cording to our findings, even combined efforts to
promote reimbursement policy are unlikely to succeed
(~40,3 %). Thus, the necessity to steer the develop-
ment of such panels towards the most cost-effective
solution, thereby increasing likelihood of reimburse-
ment, is obvious and highlights the potential of early
Technology Assessment. Furthermore, the probability
to opt for an FFPE-based NGS panel if priced at
€1000 was averaged at 44 %. Recently, Kilambi and
colleagues (2014) found that the willingness-to-pay
(WTP) for accurate test information regarding colo-
rectal cancer screening was approximately $1800 [19].
Thus, it appears that WTP has a wide variance and
could be interesting for further research.
Furthermore, demonstrating the effectiveness of guid-
ing therapy via NGS panels also may pose a problem.
While respondents expect to identify 6,6 molecular tar-
gets per patient, the number of actionable drug targets
may actually remain limited. In 30,2 % of cases, off-
label prescription will be required, which most physi-
cians would be willing to supply albeit depending on
stage of disease and level of evidence. While perhaps
helpful in some cases, these situations actually under-
line the need for accelerated evidence generation on
drug efficacy as to increase the number of registered
therapies on the market. Almost all of our respondents
deemed lower levels of evidence than traditional RCTs
valid to base medical decisions upon and without en-
couragement towards that direction, some even advo-
cated the need for more flexible (eg. basket/adaptive
protocols) and molecularly orientated designs. A recent
review by Sargent and Korn (2014) affirmed that there
has already been a major shift in the paradigm sur-
rounding cancer clinical trial designs in the past dec-
ade, in which molecular classification is gaining in
popularity [20]. Indeed, this topic is not seldom dis-
cussed at scientific-meetings and in literature. Any such
efforts are likely to benefit the clinical utility of NGS
gene panels as well and may perhaps even be pivotal in
their road to success.
Nonetheless, it will take approximately 6,5 years before
NGS gene panels become common in clinical oncology
and competition on the market can be expected to be
fierce. Since our respondents believe that there is a con-
siderable chance (45,0 %) that another novel technology
will rapidly become more popular, even within 9,6 years,
the window of opportunity for NGS gene panels is small.
Thus, timely reaching the market may be crucial for de-
velopers. We believe that our findings and suggestions
can contribute to that process.
However, our results also face several limitations.
Since NGS for diagnostics is rather complex to begin
with, some topics such as data warehouse and–integra-
tion, were not incorporated in our research yet as they
require the in-depth expertise of completely different
stakeholders. Some groups, such as patients, clinical ge-
neticists, pharmaceutical companies or health insurers
were not included in our study and should be
approached in future research. Furthermore, our results
are at risk for response bias, since respondents are likely
to have an increased interest in NGS a priori. Since we
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decided not to focus on a particular NGS panel for the
generalizability of our results, some questions elicited
vastly different opinions or outcomes. Next to the re-
sponse bias, there might also be a framing bias; a per-
son’s choice between alternatives depends on how these
alternatives are framed. Although there has been a pilot
series of 6 responders from different disciplines where
we tested the wording in case of suggestiveness, it was
not completely possible to prevent. In particular, scenar-
ios were framed positively or negatively to evoke the re-
sponder to his or her opinion, yet this may have also led
to suggestiveness of the response. Large standard devia-
tions due to (un) intentional ambiguity in language or
small sample size, disagreement or outliers can make it
difficult to draw clear-cut conclusions.
Conclusions
To our notion, we are the first to methodologically as-
sess NGS, mapping out both quantitative and qualitative
aspects that may influence adoption of this novel tech-
nology in the clinic.
We believe our findings enable readers involved in
NGS implementation to anticipate pivotal events of so-
cial, technical, clinical and financial nature (Table 2) and
if applicable, alter their strategy to improve success. For
instance, by meeting the technical specifications desired
by physicians or opting for development of user-friendly
FFPE-capable panels. Increasing adoption may also be
achieved via hosting education events (Table 5). Perhaps
even more important, will be to tackle anticipated bar-
riers for adoption. For instance, further efforts will be re-
quired to accelerate, demonstrate and perhaps improve
clinical utility of NGS panels (Table 5).
In addition, our drafted scenarios and estimates on ac-
companying parameters may be used for (the setup of )
cost-effectiveness modeling (Table 3). Such data is a
valuable starting-point at this early stage of develop-
ment, since traditional resources of information are not
yet available. Importantly, modeling outcomes alongside
development could steer NGS towards the most optimal
outcome. As reimbursement probability was also found
to be low in our study, we believe such efforts should re-
ceive high priority.
To conclude, we have taken the first steps towards sci-
entific input for reimbursement decisions, thereby po-
tentially accelerating the route from bench-to-bedside.
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Table 5 Recommendations to promote adoption of NGS in clinical oncology
Domain Recommendation
Social ▪ Further investigate patients’ perspective
▪ Organize additional training on pharmacogenomics for physicians.
Technical ▪ Use desired technical specifications as a guideline for development of a NGS panel.
▪ Develop user-friendly FFPE-capable NGS panels.
Reimbursement ▪ Further investigate willingness-to-pay
▪ Set cost-effectiveness as a high priority to facilitate reimbursement.
Clinical utility and evidence generation ▪ Advocate novel evidence generation designs.
Market access ▪ Enter the market rapidly to maximize window of opportunity
FFPE fresh frozen paraffin embedded [tissue preservation]
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